CHE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -12.53%, SMA50 -10.91%, SMA200 -14.66%). The stock’s 14-day RSI is 27.31 (weak momentum), while the ATR of 16.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.4% below its high and over -2.89% above its low. Average 10-day trading volume of 228.65 thousand shares is in line with the 3-month average of 219.34 thousand, indicating normal recent market interest.

Chemed Corporation generated EPS of $18.91 over the past year. Five-year average earnings growth is 8.37%. Wall Street analysts project EPS growth of 11.36% annually over the next five years. The latest quarter delivered EPS of $5.27. The next quarter is forecast at $5.99. Next year's EPS is expected at $11.14. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $650.00 to $475.00. The high target offers 70.78% upside. The low target suggests 24.8% downside. The mean target is $573.00. This offers 50.55% upside. Chemed Corporation earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -2.23%. The prior quarter beat by -10.67%. Over the last six quarters, Apple has recorded several small beats. These include -1.26% in July 24, 2024.

Chemed Corporation (NYSE:CHE) closed at $380.60 USD, gaining $3.03 (0.80%) from the previous close of $377.57. The stock is currently within 5% of its 52-week low $365.21 and $604.91. With a market capitalization of about $5.37 billion, Chemed Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 230.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Cincinnati, OH, Chemed Corporation operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Kevin J. McNamara, the company employs approximately 15,695 people and listed since May 03, 1973. Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.

Chemed Corporation last paid a dividend of 2.3 per share, this equals a trailing yield of roughly 0.28%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $761.79. This means the shares are trading below this model’s fair value.

Chemed Corporation has 14.57 million shares outstanding. The public float is 14.28 million shares, elevated short interest at 3.26% of float. This equals 410.22 thousand shares. The short ratio is 2.18 days. Institutional investors hold 99.95% of the float. Insiders own 1.98%. MCNAMARA KEVIN J holds 92.22 thousand shares, HUTTON THOMAS C has 32.76 thousand shares and LEE SPENCER S has 14.63 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.50 thousand shares across 3 transactions.

Chemed Corporation trades at a P/E ratio of 20.08, slightly below the S&P 500 average, with a price-to-sales ratio of 2.12 and a price-to-book ratio of 5.44 trading at moderately above to book value. The P/FCF stands at 16.5, also below market averages.

Chemed Corporation (NYSE:CHE) shares are flat 5.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Chemed Corporation trading at a premium to the broader market with a P/E of 20.08. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $395.09, suggesting 3.81% upside. Our AI forecast model points to short-term weakness (-10.13% over two weeks), a medium-term fall (-44.47% over three months), and a longer-term loss (-8.1% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Chemed Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.13%, with price expected at $342.06 by April 16, 2026, within a range of $321.80 to $362.17 3-Month Outlook: Projected fall of -44.47%, reaching $211.33 by July 01, 2026, with a range of $189.11 to $224.95. 1-Year Outlook: Projected loss of -8.1%, with price at $349.76 by April 02, 2027, within a range of $326.99 to $367.81.